Cannabidiol (CBD) and Older Adult Cannabis Users Study

This study is looking at how different types of cannabidiol (CBD) affect older adults who use cannabis. We want to understand if full spectrum CBD (fsCBD), which contains 200mg CBD and 4mg THC, or broad spectrum CBD (bsCBD), which has 200mg CBD without THC, can help with pain, anxiety, depression, and sleep. Participants will be randomly assigned to receive fsCBD, bsCBD, or a placebo (an inactive pill). We'll measure changes in your movement, balance, and anxiety levels over 8 weeks. You may be able to join if you are at least 60 years old, have used cannabis before without problems, and haven't used cannabis regularly in the last six months. Your liver function will also be checked.

Study design
This is an interventional study with 385 participants. Participants will be randomly assigned to one of three groups: fsCBD, bsCBD, or placebo.
What's involved
You would participate for 8 weeks, with measurements taken at the start, 4 weeks, and 8 weeks.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 8 weeks, with the last measurements taken at that time.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06290063

Cannabidiol and Older Adult Cannabis Users

Recruiting
PHASE2Ages 60+InterventionalTreatment
University of Colorado, Boulder
~385 participants
Updated 2026-06-10 on ClinicalTrials.gov
What's tested:fsCBD CannabidiolbsCBD CannabidiolPlacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Subjective Motor Function
Measured over Baseline, 4 weeks, 8 weeks
+15 more outcomes measured
Sleep
Anxiety
Depression
Pain
1 sites across 1 states
Colorado1

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

At least 60 years of age
Able to provide informed consent
Must have used a cannabis product at least once with no negative effects
Must not have been regularly using any cannabis products (\<3x/month) in the last 6 months
Female participants must be postmenopausal
Liver function tests (Alanine transaminase (ALT) and
Aspartate transaminase (AST)) must show levels no greater than 2x the upper normal limits for age
Must be currently taking medication/s for pain, sleep, and/or mood

Exclusion

Blood alcohol level \> 0 at screening (to sign consent form)
Report of other drug use (cocaine, opiates, methamphetamine) in the past 90 days or fail urine screen for any of these drugs
Past or current diagnosis, or family history of diagnosis of psychosis
Current use of anti-epileptic medications (e.g. clobazam, sodium valproate)
Current use of medications known to have major interactions with Epidiolex (buprenorphine, leflunomide, levomethadyl acetate, lomitapide, mipomersen, pexidartinib, propoxyphene, sodium oxybate, and/or teriflunomide).
Current use of antipsychotic medications
Currently undergoing chemotherapy (to prevent drug interactions)
  • Subjective Motor FunctionBaseline, 4 weeks, 8 weeks

    Activities-specific Balance Confidence Scale. Participants asked about confidence in completion of 16 daily tasks without losing balance or becoming unsteady. Responses are on a scale from no confidence to completely confident, with higher aggregate scores meaning higher subjective motor function.

  • BalanceBaseline, 4 weeks, 8 weeks

    Dynamic sway (balance) measured via an app on a standard smartphone which will be attached to the participant's waist using a Velcro strap.

  • AnxietyBaseline, 4 weeks, 8 weeks

    Beck Anxiety Inventory. 21 question survey. Each question is answered from 0 (not at all) to 3 (severely), where higher scores suggest higher anxiety. Total scores are between 0-63, where anything above 36 suggest potentially concerning levels of anxiety.

  • DepressionBaseline, 4 weeks, 8 weeks

    Beck Depression Inventory. 21 question survey. Each question is answered from 0 (not at all) to 3 (severely), where higher scores suggest higher depression. Total scores are between 0-63, where anything above 40 suggest potentially concerning levels of depression.

  • Blood Cytokine LevelsBaseline, 4 weeks, 8 weeks

    Blood cytokine levels will be measured from biological samples. Includes blood levels of cytokine inflammatory markers (IL6, TNF-α, IL-β, and CRP)

  • Depression/AnxietyBaseline, 4 weeks, 8 weeks

    Depression Anxiety Stress Scale - 21 Item (DASS-21). Scores are between 0 and 63, with higher scores indicating more negative emotional states.

  • Drug Effects4 weeks, 8 weeks

    Drug Effects Questionnaire (DEQ). Six questions about drug effects with possible answers of "not at all", "somewhat", and "extremely", where higher scores indicate higher drug effects.

  • Inhibitory ControlBaseline, 4 weeks, 8 weeks

    Flanker Inhibitory Control and Attention Task

  • Cognitive FunctionBaseline, 4 weeks, 8 weeks

    Functional Assessment of Cognitive Function - Cognitive (FACT-Cog). Scores are transformed such that scores range from 0-132 and higher scores indicate a better quality of life/cognitive function.

  • Pain Intensity and InterferenceBaseline, 4 Weeks, 8 Weeks

    Brief Pain Inventory - Short Form (BPI - SF). Measures pain levels, pain interference, and relief from medication, and includes diagrams for labeling pain.

  • Cognitive AbilityBaseline, 4 weeks, 8 weeks

    Digital Symbol Substitution Test (DSST) assesses global cognitive ability

  • Pain IntensityBaseline, 4 weeks, 8 weeks

    PROMIS (Patient-Reported Outcomes Measurement Information System) Pain Intensity (7-day). Scores are between 1-5, with 1 being no pain and 5 being very severe. Assessed with 2 items as well as current pain.

  • Change in Condition4 weeks, 8 weeks

    Patient Global Impression of Change (PGIC). 7 point scale assessing subjective changes in participant's condition.

  • Sleep DisturbanceBaseline, 4 weeks, 8 weeks

    PROMIS (Patient-Reported Outcomes Measurement Information System) Sleep Disturbance 4a. Scores are separated between the first question (sleep quality) and the remaining 7 questions. For the first question, scores are between 1 and 5, with 1 being very poor sleep quality and 5 being very good sleep quality. The remaining 7 questions are scored individually on a scale of 1--5; for some questions, higher scores mean less disturbance, and for others, a higher score means more disturbance.

  • Sleep-Related ImpairmentBaseline, 4 weeks, 8 weeks

    PROMIS (Patient-Reported Outcomes Measurement Information System) Sleep-Related Impairment 4a. Scores are between 4 and 20, with higher scores indicating more sleep-related impairment

  • MemoryBaseline, 4 weeks, 8 weeks

    Rey auditory verbal learning test assesses verbal memory.